MK-8226

MK-8226 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-8226, covering 2016-06-09 to 2016-06-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) [Phase 1]